miRecule Announces Strategic Collaboration with EMS Group Company Rio Biopharma to Advance Targeted Delivery of RNA Therapeutics
miRecule, Inc., a biotechnology company developing next-generation RNA therapeutics for rare genetic diseases, today announced a strategic research collaboration with Rio Biofarma Brasil Ltda. (RBBL), part of EMS S.A., Brazil’s largest pharmaceutical company. The partnership will focus on the co-development of peptide-mediated delivery technologies intended to improve targeted delivery of RNA therapeutics to extra-hepatic tissues across a broad range of disease areas.
RNA therapeutics have the potential to address unmet medical need by enabling precise intervention at the genetic level. While major progress has been achieved in liver- and muscle targeted applications, delivering RNA to additional tissue types remains a key challenge. This collaboration aims to advance next-generation delivery approaches designed to expand the tissues accessible to RNA medicines.
Under the agreement, miRecule and RBBL will pair miRecule’s proprietary NAVIgGator™ platform—which supports the design of precision RNA medicines—with RBBL’s expertise in peptide discovery, development, and manufacturing. Together, the companies will develop novel peptide–RNA conjugates capable of enabling delivery of RNA therapeutics to new tissue targets.
